Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine

Human hepatocyte transplantation has been actively perused as an alternative to liver replacement for acute liver failure and liver-based metabolic defects. current challenges in this field include a limited cell source, reduced cell viability following cryopreservation and poor engraftment of cells into the recipient liver with consequent limited life span. as a result, alternative stem cell sources such as pluripotent stem cells, fibroblasts, hepatic progenitor cells, amniotic epithelial cells and mesenchymal stem/stromal cells (mscs) can be used to generate induced hepatocyte like cells (hlc) with each technique exhibiting advantages and disadvantages. hlcs have comparable function to primary human hepatocytes and could offer patient-specific treatment. however, long-term functionality of transplanted hlcs and the potential oncogenic risks of using stem cells have yet to be established. the immunomodulatory effects of mscs are promising, and multiple clinical trials are investigating their effect in cirrhosis and acute liver failure. here, we review the current status of hepatocyte transplantation, alternative cell sources to primary human hepatocytes and their potential in liver regeneration. we also describe recent clinical trials using hepatocytes derived from stem cells and their role in improving the phenotype of several liver diseases.